(2004) Global Tuberculosis Control: surveillance, planning, financing,

(1993) Korean Academy of Tuberculosis and Respiratory Diseases,

(1997) Tuberculosis in Korea-yesterday,today and tomorrow,

(2000) Targeted tuberculin testing and treatment of latent tuberculosis infection,

(2000) Anti-Tuberculosis Drug Resistance in the World,

(2003) Guidelines for the control of tuberculosis , Korean National Institute of Health

(1998) Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population,

(2002) The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systeꠀmic lupus erythematosus and rheumatoid arthritis patients in Korea,

(1997) Is pulmonary tuberculosis a major risk factor on patient and graft survival in kidney transplantation,

(2003) Treatment of tuberꠀculosis: guidelines for national programmes, World Health Organization

(2002) Clinical pracꠀtice. Latent tuberculosis infection,

(2002) Global drugꠀresistance patterns and the management of latent tuberculosis infection in immigrants to the United States,

(2001) Incidence of pulmonary tuberculosis in Korean civil servants: second study,

(2003) The treatment of tuberculosis in South Korea,

(2003) Annual report on the notified tuberculosis patients in Korea (2002.1- 2002.12),

(1999) Tuberculosis situation in Korea,

(1999) Tuberculosis control in Korea.Hallym Health Forum,

(2004) Priorities for the treatment of latent tuberculosis infection in the United States,

(1999) Spectrum of opportunistic infections and malignancies in patients with human immunodeꠀficiency virus infection in South Korea,

(2003) Contacts of tuberculosis patients in high-incidence countries,

(1974) The proꠀgnosis of a positive tuberculin reaction in childhood and adolescence,

(2003) Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak,

(2001) Transmission of Mycobacterium tuberꠀculosis among high school students in Korea,

(1978) Prophylaxis with isoniazid in inactive tuberculosis.A Veterans Administration Cooperative Study XII,

(1972) The risk of tuberculosis in patients with fibrous lesions radiologically diagnosed,

(1995) Report on the 7th tuberꠀculosis prevalence survey in Korea,

(1938) The residual infecꠀtivity of the primary complex of tuberculosis,

(1927) Tubercle bacilli in latent tuberculosis lesions and in lung tissue without tuberculous lesions,

(respirmed1993) Is tuberculosis chemoprophylaxis necessary for patients receiving corticosteroids for respiratory disease,

(2001) Mycobacterial infection after kidney transplantation:single center experience,

(2001) Tuberculosis associated with infliximab,a tumor necrosis factor alpha-neutralizing agent,

(2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report,

Occurrence of tuberculous pleurisy assoꠀ ciated with infliximab therapy, in press

(2000) Diagnostic Standards and Clasꠀsification of Tuberculosis in Adults and Children,

(bmj1890) An address on bacteriological research,

Frequency of tuberculosis in childꠀ,

(2000) A clinician's guide to tuberculosis, Lippincott Williams & Wilkins

(1999) Cytokine/chemokine cascades in immunity to tuberculosis,

(1941) Tuberculin purified protein derivative;preparation and analysis of a large quantity for standard,

(1978) Skin test antigens:an evaluation whose time has come,

(1958) Preparation of puriꠀfied tuberculin RT 23,

(1964) A Comparison in the United States of America of Two Tuberculins,Ppd-S and Rt 23,

(1964) A Study of Variability in Tuberculin Test Reading,

(1975) Editorial:Measurement of delayed skin- test responses,

(1995) Interpretation of the tuberculin skin test,

(1999) Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion,

(microbiolrev1978) a review of their isolation,

(1981) Antigens of PPD,old tuberculin,and autoclaved Mycobacterium bovis BCG studied by crossed immunoelectrophoresis,

(1996) Detection and idenꠀtification of non-tuberculous mycobacterial infecꠀtions in 6,472 tuberculosis suspected patients,

(pediatrinfectdis1983) The use of purified protein deriꠀ vative mycobacterial skin test antigens in children and adolescents purified protein derivative skin test results correlated with mycobacterial isolates,

(1996) Non-specific tuberculin reactivity due to sensitization to non-tuberculous mycobacꠀ in children not vaccinated with BCG Diagnostic value of a comparison of intradermal tests with tuberculin and NTM antigens,

(1971) Tuberculin sensitivity eight to fifteen years after BCG vaccination,

(1972) Correlation between tuberculin sensitivity after 2 months and 5 years among BCG vaccinated subjects,

(1987) Tuberꠀculin response of Sri Lankan children after BCG vaccination at birth,

(2002) A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements,

(2003) Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection ters for Disease Control and Prevention,

(2001) Comparison of a whole-blood interferon gamma assay with tuberꠀculin skin testing for detecting latent Mycobacꠀterium tuberculosis infection,

(2002) Evaluation of a whole- blood interferon-gamma release assay for the deteꠀction of Mycobacterium tuberculosis infection in 2 study populations,

(2004) Comparison of a new specific blood test and the skin test in tuberculosis contacts,

(2004) Specific detection of tuberculosis infection an interferon-gamma based assay using new antigens,

(amrevrespirdis1989) mental short-course preventive therapy of tuberꠀ culosis with rifampin and pyrazinamide,

International Union Against Tuberculosis Commitꠀ tee on Prophylaxis Efficacy of various durations of isoniazid preventive therapy for tuberculosis five years of follow-up in the IUAT trial,

(1999) How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?,

Epidemiological basis of tuberculosis eradication The isoniazid trial in Greenland,

(amrevrespirdis1967) trolled trial of community-wide isoniazid prophyꠀ laxis in Alaska,

(1979) Isoniazid prophylaxis among Alaskan Eskimos:a final report of the bethel isoniazid studies,

(2001) Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults,

(1962) Isoniazid metabolism and its clinical implications in Koreans,

(1970) A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis,

(1963) Microbiologicully cletenꠀmined isoniuzid concentrutions in the tissues of animcl and man,

(2003) Treatment of tuberculosis,

(1998) Chemotherapy and management of tuberculosis in the United Kingdom: recommenꠀdations,

(1992) A double-blind placebo-controlled clinical trial of three antituberculosis chemoproꠀphylaxis regimens in patients with silicosis in Hong Kong,

(1996) Rifampin preventive therapy for tuberculosis in Boston's homeless,

(1998) Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis,

(1997) A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus,

gonism between isoniazid and the combination pyrꠀ azinamide-rifampin against tuberculosis infection in mice,

(2000) Control and prevention of tuberculosis in the United Kingdom: code of practice 2000,

(2002) Cost- effectiveness of tuberculosis prophylaxis after releꠀase from short-term correctional facilities,

(2000) Rifampin and pyrazinamide vs isoniazid for prevention of tuberꠀ culosis in HIV-infected persons: an international randomized trial,

(2002) Death associated with rifampin and pyrazinamide 2-month treatment of latent mycoꠀbacterium tuberculosis,

(2002) Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection:a multicenter clinical trial,

(2001) Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberꠀculosis infection-New York and Georgia, 2000,

(2003) Update: adverse event data and revised American Thoracic Society/CDC recomꠀmendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States,

(2001) Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberꠀculosis infection, and revisions in American Thoꠀracic Society/CDC recommendations-United States, 2001,

(2001) Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberꠀculosis infection, and revisions in American Thoꠀracic Society/CDC recommendations-United States, 2001,

(2002) Updaꠀte: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection,

(2002) Update:Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection,

(2002) Safety and tolerability of intermittent rifampin/ pyrazinamide for the treatment of latent tuberꠀculosis infection in prisoners,

(2002) Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County,

(2002) Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection:experience from three public health tuberculosis clinics,

(2003) Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberꠀculosis,

(2003) Pyrazinꠀamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity,

(2002) Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis,

(2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis,

(2003) Latent tuberculosis in pregnancy:screening and treatment,

(2002) Treatment of isoniazid- resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months,